IL-15 (mutant) (human):Fc (mouse) (rec.) (Biotin)

CHF 570.00
In stock
CHI-HF-21115MBI-11 VialCHF 570.00
More Information
Product Details
Synonyms Interleukin-15
Product Type Protein
Properties
Source/Host CHO cells
Sequence

The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of mouse IgG2a.

Crossreactivity Human
Label/Conjugates Biotin
Biological Activity

This mutant IL-15/Fc fusion protein specifically binds to the IL-15R, competitively inhibits IL-15-triggered cell proliferation, promotes transplant tolerance, does not activate the STAT-signaling pathway, and exerts a prolonged circulating half-life caused by the modified Fc domain.

Purity ≥98% (SDS-PAGE)
Endotoxin Content <0.06EU/μg protein (LAL test; Lonza).
Formulation Lyophilized. In PBS and 0.09% sodium azide.
Other Product Data

NCBI reference NP_751914.1: IL-15 (human). The vial contains 20µg.

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 6 months after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Rα, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.

Application: Useful for immunofluorescent staining and flow cytometric analysis to identify and enumerate IL-15Rα expressing cells within mixed cell populations.

Product References
  1. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity: Y.S. Kim, et al.; J. Immunol. 160, 5742 (1998)
  2. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection: S. Ferrari-Lacraz, et al.; J. Immunol. 167, 3478 (2001)
  3. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance: X.X. Zheng, et al.; Immunity 19, 503 (2003)
  4. Limiting γc expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors: C.M. Smyth, et al.; Blood 110, 91 (2007)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.